FMP
BriaCell Therapeutics Corp.
BCTX
NASDAQ
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
4.04 USD
0.03 (0.743%)
Valuation Date:
Mar 27, 2025 4:00 PM
Share Price on Valuation Date
$4.04
Stock Beta
1.857
Shares Outstanding
3709440